However, recent molecular targets have shown high penetration of the BBB and improved clinical outcomes for subgroups of patients with EGFR-mutated (EGFRm) NSCLC and LM [1, 3, 9–12]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.